The Clinical Presentation of Thrombotic Microangiopathy

Article Sidebar

PDF
Published: Mar 26, 2025
DOI: https://doi.org/10.47191/ijpbms/v5-i3-10
Keywords:
HUS, renal replacement therapy, coma, vena cava thrombosis

Main Article Content

Guliko Kiliptari
Head of critical care department of university clinic after N.Kipshidze. MD, PhD.,Prof.of TSMU (Tbilisi, Georgia).
Nino Agladze
Invited Lecturer. Tbilisi state university (Tbilisi .Georgia)

Abstract

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and end organ damage. Microangiopathic haemolytic anaemia is caused by red blood cell fragmentation in the microvasculature, with schistocytes seen on peripheral blood film. Lactate dehydrogenase (LDH) is raised due to tissue ischemia and cell lysis. Low plasma haptoglobin is a marker of haemolysis as it binds to free haemoglobin and the complex is cleared by macrophages. Coombs test is gener negative. Renal involvement is common to most TMAs due to its vulnerability to occlusion and endothelial damage.

Article Details

How to Cite
Guliko Kiliptari, & Nino Agladze. (2025). The Clinical Presentation of Thrombotic Microangiopathy . International Journal of Pharmaceutical and Bio Medical Science, 5(3), 209–214. https://doi.org/10.47191/ijpbms/v5-i3-10
Issue
Vol. 5 No. 3 (2025): Volume 05 Issue 03 March 2025
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Diagnosis and treatment of thrombotic microangiopathy Gemma L Thompson 1,2, David Kavanagh 1,2,✉ Int J Lab Hematol 2022 Sep 8;44(Suppl1):101–113. doi: 10.1111/ijlh.13954Clinical Evaluation and

II. Management of Thrombotic Microangiopathy Joshua Leisring, Sergey V. Brodsky, Samir V. Parikh : 23 August 2023

https://doi.org/10.1002/art.42681

III. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300‐317. [DOI] [PMC free article] [PubMed] [Google Scholar]

IV. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589‐600. [DOI] [PubMed] [Google Scholar]

V. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819‐826. [DOI] [PubMed] [Google Scholar]

VI. Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune‐mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466‐471. [DOI] [PubMed] [Google Scholar

VII. Atypical Hemolytic-Uremic Syndrome: A Case Report and Literature ReviewArsalan Rafiq,A,B,C,D,E,F Hassan Tariq,A,B,C,E,F Naeem Abbas,E,F and Roopalekha ShenoyA,E,, Am J Case Rep. 2015; 16: 109–114.Published online 2015 Feb 24. doi: 10.12659/AJCR.892907

VIII. Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome: Review of Literature of the Autoimmune Form of HUS. Marie-Agnes Dragon-Durey,Caroline Blanc,Nature reviews Nephrology8,622-633,November2012 doi:10.1038/neph. 2012.

IX. Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from DIC in adults.PARK IA-AM j Clin Pathol-01-MAR-2010;133(3):460-5

X. Therapeutic plasma exchange in patients with TTP-HUS :the 10 year experience of a single center.Kirn -Hematology -01-MAR-2011;16(2):73-9

XI. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Nester CM, Thomas CP. Eur J Intern Med. 2013;24(6):486–91. [PubMed]

XII. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol. 2014;18(1):4– [PubMed]

XIII. Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Bauer A, Loos S, Wehrmann C, et al. Pediatr Nephrol 2014; 29:1607.

XIV. Thrombotic microangiopathy(TTP and HUS):advances in differentiation and diagnosis.Schneide M-Clin Lab SCI-oi-oct-2007;20(4):216-20

XV. Interventions for hemolytic-uremic syndrome and thrombotic-thrombocytopenic purpura,a systematic review of randomized contolled trials.Michaelem-AM j Kidney dis-01-Feb-2009;53(2):259-72

XVI. A Case Report and Literature Review of Eculizumab Withdrawal in Atypical HemolyticUremic Syndrome. Borja Quiroga ,Alberto de Lorenzo ,Cristina Vega ,Fernando de Alvaro, Am J Case Rep, 2016; 17: 950-956

XVII. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Nathanson S, Kwon T, Elmaleh M, et al. Clin J Am Soc Nephrol 2010; 5:1218.

XVIII. Atypical hemolytic uremic syndrome-Kavanagh D-Curr opin hematol-01-Sep-2010;15(5):432-8

XIX. Is there a shared pathophysiology for TTP and HUS?-Desch K-j.AM Soc Nephrol-01 sep-2007;18(9):2457-60

XX. HUS and atypical HUS. Blood. 2017 May 25; 129(21): 2847–2856.

XXI. oh CH, Alhamdi Y, Abrams ST. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation. Ann Lab Med. 2016;36(6):505-512. [PMC free article] [PubMed] [Google Scholar]

XXII. Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: State of the art. Mol Immunol. 2015;67(1):31-42. [PubMed] [Google Scholar]

XXIII. Kielstein JT, Beutel G, Fleig S, et al. ; Collaborators of the DGfN STEC-HUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27(10):3807-3815.[PubMed] [Google Scholar]

XXIV. Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164(6):759-766. [PMCfree article] [PubMed] [Google Scholar]